Andrea Ardizzoni

Host-derived immunometabolic biomarkers identify prognostic profiles under immunotherapy in advanced NSCLC: the SARC-LUNG study

Andrea De Giglio, Maria Conte, Simona Coco, Francesco Galuppi et autres

it (code pays fourni par la source)

Prognostic value of different metabolic response criteria in patients with advanced melanoma treated with immunotherapy: a comparative analysis of PECRIT, PERCIMT, and EORTC criteria

Andrea Di Giorgio, Francesca Comito, Norma Bonazzi, Giacomo Battisti et autres

it (code pays fourni par la source)

Supplementary Data1 from Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco

Eleonora Gariazzo, Arielle Elkrief, Kyle Concannon, Daniele Ognissanti et autres

Data from Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco

Eleonora Gariazzo, Arielle Elkrief, Kyle Concannon, Daniele Ognissanti et autres

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non–small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial—HYPERBOLIC Study

Ludovica Mollica, Elena Tassi, Anna Copaloni, Irene De Simone et autres

it, my, es, us, fr (code pays fourni par la source)

Host-Derived Immunometabolic Biomarkers Identify Prognostic Profiles under Immunotherapy in Advanced NSCLC: the SARC-LUNG Study

Andrea De Giglio, Maria Conte, Simona Coco, Francesco Galuppi et autres

it (code pays fourni par la source)

Management of periungual pyogenic granulomas due to EGFR inhibitors in real world

Luca Rapparini, Ginevra Martelli, Stephano Cedirian, Francesca Pampaloni et autres

it (code pays fourni par la source)

Immunotherapy beyond progression combined with platinum-based chemotherapy after primary resistance to first-line immunotherapy in patients with advanced NSCLC and PD-L1 ≥50%

Andrea De Giglio, L Zullo, Alessandro Di Federico, Massimiliano Cani et autres

it, fr, nl, es, us (code pays fourni par la source)

Data from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu et autres

Supplementary Figure 6 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu et autres

Supplementary Figure 9 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu et autres

Supplementary Figure 7 from First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC

Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu et autres